Filing Patents in India: Guide for Foreign Companies & Inventors

Why India Matters for Your Global Patent Portfolio

India's patent landscape has undergone a dramatic transformation. Domestic patent filings surged from 12,040 in 2014 to over 63,000 in 2024 — a 425% increase. Total IP filings reached 6.90 lakh in FY 2024-25, up 44% in five years. India now ranks among the top five patent filing destinations globally, and its Global Innovation Index ranking improved to 38th in 2025. For foreign companies with technology-driven products or processes, filing patents in India is no longer optional — it is a strategic necessity for protecting market position in one of the world's fastest-growing economies.

This article is part of our Complete Guide to IP Protection in India for Foreign Companies. Here we dive deep into the patent filing process, costs, and prosecution strategy specifically for foreign applicants.

The Indian Patent Office (IPO) operates under the Patents Act, 1970 (as amended by the Patents Amendment Act, 2005, bringing India into TRIPS compliance), and the Patents (Amendment) Rules, 2024. The 2024 rules introduced significant changes — most notably shortening the Request for Examination deadline from 48 months to 31 months — that directly affect filing strategy for foreign companies. Understanding these changes, along with India's unique patentability exclusions under Section 3, is essential for avoiding costly mistakes.

Filing Routes: PCT National Phase vs Direct Filing

Foreign companies have two primary routes to file patents in India. The vast majority use the PCT (Patent Cooperation Treaty) route, but direct filing has specific advantages in certain situations.

PCT National Phase Entry (Preferred Route)

The PCT route allows foreign companies to file a single international application under the Patent Cooperation Treaty and then enter the national phase in India (and other PCT member states) within the prescribed deadline. This is the preferred route for most foreign filers because it provides:

• Up to 31 months from the earliest priority date to decide on India filing
• The benefit of international search and preliminary examination reports to inform prosecution strategy
• A single filing date that is recognised across all designated countries
• Cost deferral — national phase fees are paid only when you decide to enter India

The critical deadline is 31 months from the earliest priority date (or the international filing date if no priority is claimed). Under the Patents (Amendment) Rules, 2024 effective March 15, 2024, it is possible to extend entry by up to 6 months with payment of an extension fee, but this should be treated as a last resort — not a planning assumption.

Direct National Filing

A foreign company can file a patent application directly with the Indian Patent Office without going through the PCT system. This route is used when:

• The invention is India-specific and the company does not need international protection
• The PCT deadline has been missed and the Paris Convention priority period (12 months) is still available
• The company wants to establish the earliest possible Indian filing date

For direct national filing, the application is filed at the appropriate patent office based on where the applicant's address for service in India (typically the patent agent's office) is located. India has four patent office branches: Delhi, Mumbai, Chennai, and Kolkata.

Required Documents and Forms

Whether filing through PCT national phase or directly, foreign applicants must submit the following:

Form 3 is uniquely important for foreign filers. India requires applicants to disclose all corresponding patent applications filed anywhere in the world — both at the time of filing and on an ongoing basis. Failure to comply with Form 3 can be grounds for revocation of the granted patent. This is a strict compliance requirement that has no equivalent in most other jurisdictions.

Filing Fees for Foreign Companies

Patent fees in India vary significantly based on the applicant's classification. Most foreign companies are classified as "large entities" unless they qualify as a DPIIT-recognised startup or meet the small entity turnover threshold (annual turnover below INR 40 lakhs).

For a typical foreign company filing through PCT national phase with 40 pages and 15 claims, the total government fees to get to examination would be approximately:

• Filing fee: INR 8,000
• Additional pages (10 pages): INR 8,000
• Additional claims (5 claims): INR 8,000
• Request for Examination: INR 25,000
• Total: INR 49,000 (approximately USD 590)

Adding professional fees for an Indian patent agent (INR 30,000-80,000 for filing and INR 25,000-60,000 for prosecution), the total cost to grant for a large entity typically ranges from INR 65,000 to INR 1,50,000 (USD 780-1,800). This makes India one of the most affordable jurisdictions globally for patent protection — a fraction of US, EU, or Japanese costs.

The Patents (Amendment) Rules, 2024 introduced a 10% discount on government fees when paying electronically for 4 or more years of renewals in advance.

The 31-Month Deadline: What Changed in 2024

The Patents (Amendment) Rules, 2024, effective March 15, 2024, introduced the most significant procedural change in recent years: the Request for Examination (RFE) deadline was shortened from 48 months to 31 months from the priority date or Indian filing date.

Impact on Foreign Filers

This change has three critical implications:

1. Compressed decision timeline: Foreign companies now have less time to evaluate whether India prosecution is worthwhile. Under the old rules, you had 48 months — nearly 4 years — to assess market potential and competitive landscape before requesting examination. Now you have 31 months.
2. Aligned with PCT national phase entry: The 31-month RFE deadline aligns with the PCT national phase entry deadline, meaning that for PCT filers, the RFE should be filed simultaneously with or shortly after national phase entry. There is no longer a gap between entry and examination request.
3. Third-party observations also aligned: The period for filing third-party observations (representations under Section 25(1)) is also aligned to 31 months, reducing the window for pre-grant challenges.

Strategic Response

Foreign companies should adjust their IP management processes to account for the compressed timeline. Set calendar alerts at the 28-month mark from the priority date to ensure adequate time for filing decisions. If you are uncertain about India prosecution, file the national phase entry and RFE by the 31-month deadline and evaluate during prosecution — the cost of filing (INR 33,000 for a large entity) is modest compared to the cost of losing patent rights in a market of 1.4 billion people.

Section 3 Exclusions: What You Cannot Patent in India

India's Patents Act contains several notable patentability exclusions under Section 3 that foreign companies — particularly in technology, pharma, and biotech — must understand. These exclusions go beyond what is typical in the US, EU, or Japan.

Section 3(d): New Forms of Known Substances

India does not grant patents for mere new forms, derivatives, or polymorphs of known substances unless the applicant demonstrates significantly enhanced efficacy. This is the "evergreening" prohibition, primarily targeting pharmaceutical companies that attempt to extend patent life through incremental modifications. The landmark 2013 Supreme Court decision in Novartis v. Union of India established the high threshold for demonstrating "enhanced efficacy" under this section.

Section 3(k): Computer Programs Per Se

Computer programs per se, mathematical methods, business methods, and algorithms are excluded from patentability. However, this does not mean software-related inventions are unpatentable in India. The Indian Patent Office released the Revised Guidelines for Examination of Computer Related Inventions (CRI) in 2025, introducing structured tests for these exclusions.

The key to patenting software-driven inventions in India is claim construction. Claims must be drafted to emphasise:

• The technical effect produced by the software (not the algorithm itself)
• The hardware-software interaction or system-level innovation
• The technical problem solved by the invention
• The novel technical architecture (not merely the business process)

A US software patent application filed verbatim in India will very likely be rejected under Section 3(k). Indian patent agents experienced in CRI prosecution can restructure claims to navigate this exclusion — this is a standard and well-understood practice, not an insurmountable barrier.

Section 3(j): Biological Processes

Plants and animals (other than microorganisms), and essentially biological processes for their production, are not patentable. This affects biotech companies dealing with plant varieties, animal breeding, and certain agricultural innovations.

Section 3(i): Diagnostic and Treatment Methods

Methods of diagnosis, treatment, or surgery on humans or animals are not patentable. Medical device companies must frame claims around the device or system, not the diagnostic or treatment method it enables.

Expedited Examination: Fast-Tracking Your Indian Patent

India offers an expedited examination pathway that can reduce the time to First Examination Report (FER) from 12-24 months to just 1-3 months. For foreign companies with time-sensitive IP, this is a significant strategic tool.

Eligibility Categories

As of 2025-2026, the following categories are eligible for expedited examination under Rule 24C:

• DPIIT-recognised startups — Including Indian subsidiaries of foreign companies that qualify under Startup India
• Small entities under MSME Act, 2006 — Annual turnover below INR 40 lakhs
• Female applicants — Natural persons who are female
• PCT applicants designating India as ISA/IPEA — Foreign companies that named India as the International Searching Authority or International Preliminary Examining Authority
• Government departments and institutions
• Educational institutions

For most foreign companies, the PCT ISA/IPEA route is the most accessible pathway to expedited examination. This requires designating India as the ISA or IPEA in the PCT application — a decision that must be made at the international phase, not after national phase entry.

Expedited Examination Fees

The expedited fee is in addition to the regular RFE fee. For a large entity, the total to obtain expedited examination is INR 85,000 (INR 25,000 RFE + INR 60,000 expedited). Given the potential to receive an FER within 1-3 months instead of 12-24 months, this premium is often worthwhile for commercially important inventions.

Patent Prosecution Strategy in India

Once the First Examination Report (FER) is issued, foreign applicants have 6 months to respond, with a possible 3-month extension (Form 4). Effective prosecution strategy in India requires understanding the examiner's common objection patterns:

Common Objections and Responses

• Section 3(k) objections for software claims: Restructure claims to emphasise technical effect and hardware-software interaction. Provide arguments distinguishing the invention from a mere "computer program per se."
• Novelty and inventive step (Sections 2(1)(j) and 2(1)(ja)): Indian examiners follow a problem-solution approach similar to the European Patent Office. Prepare prior art analyses and demonstrate the unexpected technical advantage.
• Section 8 compliance (corresponding application disclosure): Ensure Form 3 is up to date with all worldwide filings. Examiners frequently flag incomplete Form 3 disclosures as a ground for refusal.
• Clarity and support (Section 10): Indian examiners may require claims to be more clearly supported by the specification. Overly broad claims relative to the disclosed embodiments are commonly objected to.

Divisional Applications

If the examiner raises a lack-of-unity objection (Section 10(5)), you can file one or more divisional applications covering the non-elected inventions. Divisional applications can be filed voluntarily at any time before the grant of the parent application, or in response to an examiner's direction.

Pre-Grant Opposition

Any person can file a pre-grant opposition (representation under Section 25(1)) against a published application. Foreign companies should monitor published applications by competitors in their technology space and file oppositions where appropriate. Conversely, be prepared for pre-grant oppositions on your own applications — particularly in pharma and biotech, where activist organisations and competitors frequently file representations.

Annual Renewal Fees (Patent Annuities)

Unlike trademarks, which renew every 10 years, Indian patents require annual renewal fee payments starting from the 3rd year after the filing date. These fees escalate significantly over the 20-year patent term:

For a large entity maintaining a patent for the full 20-year term, total renewal fees amount to approximately INR 6,80,000 (USD 8,200). A 10% discount applies when paying electronically for 4 or more years in advance under the 2024 Rules amendment.

Missing a renewal payment triggers a 6-month grace period during which the patent can be restored by paying the renewal fee plus an extension fee. After the grace period expires, the patent lapses permanently.

Common Mistakes Foreign Companies Make

Based on common patterns in Indian patent prosecution, these are the mistakes foreign companies should avoid:

• Missing the 31-month PCT deadline: There is no general provision for late national phase entry beyond the 6-month extension with additional fees introduced in 2024. Set calendar alerts at 28 months from the priority date.
• Filing US-style software claims verbatim: Claims that are perfectly valid in the US may be rejected under Section 3(k) in India. Invest in India-specific claim drafting with an experienced Indian agent.
• Ignoring Form 3 compliance: The ongoing obligation to disclose corresponding worldwide applications is unique to India and strictly enforced. A granted patent can be revoked for non-compliance with Section 8/Form 3.
• Not considering expedited examination: If you designated India as ISA/IPEA in the PCT application, you qualify for expedited examination. The additional INR 60,000 fee for a large entity is minimal for commercially important inventions.
• Forgetting renewal fees: Unlike many jurisdictions that send reminders, the Indian Patent Office does not proactively notify patentees of upcoming renewal deadlines. Implement a docketing system or engage a renewal service.
• Underestimating Section 3(d) for pharma: The enhanced efficacy threshold set by the Novartis decision is demanding. Pharma companies should build efficacy data into their development programs specifically for India filing strategy.

For comprehensive guidance on protecting all forms of intellectual property in India — including trademarks, designs, copyrights, and trade secrets — see our complete IP protection guide. Beacon Filing's IP registration services cover the full spectrum of intellectual property registration for foreign companies entering India.

Key Takeaways

• The 31-month deadline is absolute: PCT national phase entry and Request for Examination must both be filed within 31 months from the earliest priority date under the 2024 Rules. A 6-month extension is available with additional fees but should not be relied upon as a default strategy.
• India is extremely cost-effective: Total cost from filing to grant ranges from INR 65,000-1,50,000 (USD 780-1,800) for large entities — a fraction of US or EU costs. Annual renewal fees escalate from INR 4,000 to INR 80,000 per year over the 20-year term.
• Section 3(k) requires India-specific claim drafting: Software patents are not categorically excluded, but claims must be drafted to emphasise technical effects and hardware-software interaction. Use the 2025 CRI Guidelines as your roadmap.
• Expedited examination is available: Foreign companies that designated India as ISA/IPEA in the PCT application can receive a First Examination Report within 1-3 months instead of 12-24 months, for an additional INR 60,000 (large entity).
• Form 3 compliance is non-negotiable: Disclose all worldwide corresponding applications at filing and update within 6 months of any new filing. Non-compliance can result in patent revocation.